Format

Send to

Choose Destination
Nat Med. 1998 Oct;4(10):1131-5.

Peroral gene therapy of lactose intolerance using an adeno-associated virus vector.

Author information

1
Department of Molecular Medicine, University of Auckland School of Medicine, New Zealand. Matthew.During@mail.tju.edu

Abstract

Gene therapy is usually reserved for severe and medically refractory disorders because of the toxicity, potential long-term risks and invasiveness of most gene transfer protocols. Here we show that an orally administered adeno-associated viral vector leads to persistent expression of a beta-galactosidase transgene in both gut epithelial and lamina propria cells, and that this approach results in long-term phenotypic recovery in an animal model of lactose intolerance. A gene 'pill' associated with highly efficient and stable gene expression might be a practical and cost-effective strategy for even relatively mild disorders, such as lactase deficiency.

Comment in

PMID:
9771745
DOI:
10.1038/2625
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center